Category Archives: Inside BIO Industry Analysis

Academics Weigh In on Journal Article: “GMOs, Herbicides, and Public Health”

GMO

An article published in the New England Journal of Medicine by biotech critics Philip Landrigan and Charles Benbrook condemns the use of GMO crops and herbicides.  Ultimately, the authors offer a pair of personal recommendations calling for the EPA to delay its permit for Enlist Duo, a new combination herbicide comprising glyphosate plus 2,4-D; and urging for the mandatory labeling of GM foods. Push back on the article and Landrigan’s and Benbrook’s recommendations has been Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Joint U.S.-Brazil Communique Demonstrates Commitment to Collaboration

Rio de Janeiro, Brazil

In June, Brazilian President Dilma Rousseff met with President Barack Obama to reaffirm their commitment to strengthening traditional ties, expand trade, and investment cooperation by issuing a Joint Communique which recognizes the work sharing potential of each country. This important milestone in U.S.-Brazilian diplomatic relations underscores the importance of supporting bilateral biofuels and biomedicine innovation by eliminating obstacles to the growth of investment, research and innovation. BIO invites you to learn more about the effect Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Congress, Media Focused on Biotech Food Labeling

food label

Media coverage of the biotech food labeling debate is at a fever pitch as the Safe and Accurate Food Labeling Act (H.R. 1599) is poised to see action on the floor of the House of Representatives this week. Among the highlights: Charles Conner, former United States Deputy Secretary of Agriculture and current president and CEO of the National Council of Farmer Cooperatives wrote an op-ed in RollCall: GMOs have been around for decades, helping farmers Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

The Bio Report: What a Decade of Investment Tells Us About the Health of Biotech

Emerging Therapeutic Company Investment and Deal Trends

In this podcast, The Bio Report’s Daniel Levine interviews BIO’s Dave Thomas on the recent release of a new BIO Industry Analysis report – Emerging Therapeutic Company Investment and Deal Trends – highlighting ten years (2005-2014) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers a first-time look at the degree of collaboration across the industry’s clinical pipeline. Some of the key findings Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

State of the Industry for Emerging Therapeutic Companies

Emerging Therapeutic Company Investment and Deal Trends

Emerging therapeutic companies are at their strongest point in a decade. In our new report on investment and deal trends, the BIO Industry Analysis team shows how this segment within the biotech industry has been faring over the last 10 years. The annual aggregate totals show that for almost every funding or deal activity analyzed, 2014 was the peak year of the last decade. A strong public market, a revitalized private funding environment, and a Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,